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ABSTRACT  
Administration of semelil (ANGIPARS™) has been successful in the treatment of diabetic 
foot ulcer. Considering the improvement of blood flow and anti-inflammatory effect that are 
attributed to this drug, we investigated its effect on cardiovascular performance in rabbits with 
isoproterenol (ISO) induced myocardial injury. Animal groups included: control group; ISO 
group, received ISO 50 mg/kg s.c. for two consecutive days; S1+ISO, S5+ISO and S10+ISO 
groups, received semelil 1, 5, and 10 mg/kg/day i.p. respectively, 30 min before ISO. On the 
3rd day, electrocardiogram (ECG) and hemodynamic parameters were recorded; blood sam-
ples were taken and hearts were removed for lab investigations. 
ISO induced heart injury, ECG disturbance, raise of cardiac troponin I and significant de-
crease in LVSP (p<0.05), +dp/dt max (p<0.01), -dp/dt max (p<0.05) along with increase of 
LVEDP (p<0.01). Semelil had no significant effects on ECG and plasma cardiac troponin I. 
Impairment of +dp/dt max and -dp/dt max was significantly improved in S5+ISO and 
S10+ISO groups (P<0.05 versus ISO). In addition, LVSP and LVEDP was somewhat recov-
ered in these groups, although semelil (1 mg/kg/day) to some extent exacerbated the myocar-
dial lesions induced by ISO (P<0.05).  
Therefore, in stressful conditions, semelil may improve myocardial contractility; however, it 
may aggravate the severity of injury. 
 





Cardiovascular disease (CVD) is known 
as the major cause of disability and early 
death in both developed and developing 
countries (WHO, 2007). In this regard, cor-
onary heart disease (CHD) makes up more 
than half of all cardiovascular events in 
American population < 75 years of age 
(Thom et al., 2001). Diabetes is one of the 
nine major risk factors that are involved in 
pathogenesis of CHD (Greenland et al., 
2003; Yusuf et al., 2004). 
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Previous studies demonstrated the bene-
ficial effect of semelil, a formulated extract 
of Melilotus officinalis plant containing im-
portant compounds such as 7 hydroxy cou-
marin and flavonoids, as a new herbal drug 
in treatment of diabetic foot ulcers 
(Ebrahimi et al., 2009; Heshmat et al., 
2008). Although exact anti-ulcer mecha-
nism of semelil is not clear, this has been 
attributed to the antioxidant (Hirakawa et 
al., 2000) and anti-inflammatory properties 
(Pleşca-Manea et al., 2002) of its compo-
nents. However, Hemmatabadi et al. (2009) 
reported that non-antioxidant effects may 
be involved in the therapeutic action of 
semelil on diabetic foot ulcers. Improve-
ment in blood flow has been suggested as 
another possible effect of this agent (Bah-
rami et al., 2008). Recently, Asadi-Shekaari 
et al. (2010) showed the neuroprotective 
role of semelil in rat with focal cerebral is-
chemia. Despite the clinical use of semelil 
in Iran, less attention has been paid to the 
consequences of its administration on the 
cardiovascular system.  
Considering the possible role of this 
drug in improving blood flow and lack of 
adequate knowledge about its cardiovascu-
lar consequences, in the present study we 
investigated the pretreatment effect of sem-
elil on cardiovascular performance of ani-
mals subjected to experimental myocardial 
injury based on hemodynamic, electrophys-
iological, biochemical and histopathologi-
cal indices. 
 
MATERIAL AND METHODS 
Experimental protocol 
All experimental procedures were car-
ried out in accordance with the national 
guidelines for conducting animal studies 
(Ethic committee permission No 
86/123KA—Kerman University of Medical 
Sciences, Kerman, Iran) and performed on 
36 New Zealand white rabbits weighing 
2.5-3.5 kg. 
Animals were divided randomly into 
five groups of control (CTL), ISO, S1+ISO, 
S5+ISO and S10+ISO. In CTL group, ani-
mals received equivalent volume of dis-
tilled water i.p. as vehicle of semelil and 
ISO solutions for two consecutive days. 
ISO group received 1 ml/kg distilled water 
i.p. 30 min before ISO (50 mg/kg s.c) for 
two consecutive days. This dose of ISO was 
chosen based on our pilot study in which 
significant changes in histological, bio-
chemical and electrophysiological indices 
of heart were observed. S1 + ISO, S5 + ISO 
and S10 + ISO groups were treated with 1, 
5, and 10 mg/kg semelil (i.p.) respectively 
30 min before injection of ISO, for two 
consecutive days. We also tested the dose 
of 20 mg/ kg semelil, but due to the high 
mortality rate of animals, this dose was ex-
cluded. 
Surgical preparation and experimental 
protocol have been explained in the previ-
ous studies (Joukar et al., 2010b; Najafi-
pour et al., 2010). Briefly; on the third day 
of study, animals were anaesthetized by so-
dium thiopental (50 mg/kg of body weight, 
i.p.) and the anesthesia level was main-
tained with 1 % halothane in 30 % O2–69 % 
N2 mixture during the surgical procedure. 
The trachea was cannulated, with animals 
breathing spontaneously throughout the ex-
periment. Left carotid artery and left ventri-
cle were cannulated by two heparinized sa-
line filled (7 units/ml) catheters that were 
connected to pressure transducers and Phys-
iograph (Beckman R612, USA). At the end 
of the surgery, the gaseous anesthesia was 
discontinued. Time window for animal re-
covery from surgery was 30 min. After this 
period electrocardiogram (ECG), systolic 
and diastolic blood pressures, left ventricu-
lar systolic pressure (LVSP) and left ven-
tricular end-diastolic pressure (LVEDP) 
were recorded. The mean arterial pressure 
(MAP) was calculated by “MAP=Pd + (Ps 
− Pd)/3 formula”, where Ps and Pd are sys-
tolic and diastolic arterial pressures respec-
tively. The maximum velocity of contrac-
tion (+dp/dt max) and maximum velocity of 
relaxation (-dp/dt max) were calculated 
from the left ventricular pressure trace 
(Joukar et al., 2012). Thereafter, blood 
sample was taken for measurement of 
plasma cardiac troponin I levels as an im-
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portant biomarker for estimation of myo-
cardial injury. The hearts were taken out, 
washed with saline and fixed in 10 % buff-
ered formalin and embedded in paraffin. 
Slides were prepared and stained with he-
matoxylin and eosin (H&E) and examined 
microscopically by two pathologists blind-
ed to animals grouping. The lesions graded 
as 0 (nil); 1 (minimum, focal myocytes 
damage); 2 (mild, small multifocal degen-
eration with slight degree of inflammatory 
process); 3 (moderate, extensive myofibril-
lar degeneration and/or diffuse inflammato-
ry process); and 4 (severe, necrosis with 
diffuse inflammatory process) (Joukar et 
al., 2010a). 
Alterations in ECG, such as T wave 
changes, ST segment elevation and depres-
sion or Q wave were reported by evaluating 




Quantitative data are expressed as mean 
± SEM and comparisons were performed by 
one-way ANOVA followed by LSD post 
hoc test. Changes in ECG variables are pre-
sented as the number of animals per group 
that showed each specific disturbance. His-
topathological changes are reported qualita-
tively as the number of animals with differ-
ent grades of myocardial lesions in each 
group and statistical analysis was per-
formed using the non parametric Kruskal-
Wallis and pairwise differences by the 
Mann –Whitney U-test (Joukar et al., 2011). 
P-values < 0.05 were considered as statisti-
cally significant.  
 
RESULTS 
Hemodynamic parameters and ventricular 
function indices 
Non-significant decrease was observed 
in systolic, diastolic and mean arterial pres-
sures (MAP) of the ISO group. Semelil ad-
ministration did not show significant effect 
on these parameters when compared with 
CTL or ISO groups (Table 1). On the other 
hand, the non-significant reduction of heart 
rate in ISO group was aggravated in pres-
ence of low dose of semelil (S1+ISO group) 
(P<0.01 compared with CTL and P<0.05 
versus other groups) while, the higher doses 
of semelil had no effect on this index in 
heart injury conditions (Table 1). Injection 
of isoproterenol alone was associated with 
significant decrease in LVSP (p<0.05), 
+dp/dt max (p<0.01) and -dp/dt max 
(p<0.05) and also increase of LVEDP 
(p<0.01). These alterations were somewhat 
improved by higher doses of semelil (i.e. 5 
and 10 mg/kg) (Table 1 and Figure 1). 
However, lowest dose of semelil showed a 
non significant reduction in -dp/dt max ver-
sus ISO group (Figure 1). 
 
 
Table 1: Hemodynamic parameters and ventricular function of different groups of the study  
 
n: number of animals, CTL: control, ISO: isoproterenol, S1: 1 mg semelil, S5: 5 mg semelil, S10: 10 mg semelil, 
Ps: systolic pressure, Pd: diastolic pressure, MAP: mean arterial pressure, HR: heart rate, LVSP: left ventricular 
systolic pressure, LVEDP: left ventricular end-diastolic pressure. Data are presented as mean ± SEM. *p<0.05 





LVEDP LVSP HR MAP Pd Ps Groups 
3.6±0. 8 127±5 290±13 96±4 85±5 118±5 CTL (n=7) 
14±3** 102±8* 262±18● 85±7 74±6 107±9 ISO ( n=8) 
11±1** 108±5 224±5** 81±5 72±5 101±7 S1+ISO (n=7) 
8±1* 119±8 265±10● 88±6 77±6 111±6 S5+ISO(n=7) 
7±1# 114±9 270±12● 91±7 81±6 112±8 S10+ISO(n=7) 
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Figure 1: Maximum contraction (+dp/dt max) 
and -relaxation velocity (–dp/dt max) in different 
animal groups. Values are means ± SEM. n: 
number of animals, CTL: control, ISO: isopro-
terenol, S1: 1 mg semelil, S5: 5 mg semelil, 
S10: 10 mg semelil, +dp/dt max: maximum ve-
locity of heart contraction over time, -dp/dt max: 
maximum velocity of heart relaxation over time. 
*p<0.05 and **p<0.01 versus CTL group, 
▼p<0.05 versus ISO group, and ●●p<0.01 ver-
sus S1+ISO group 
 
TROPONIN I LEVEL 
As shown in Figure 2 the plasma level 
of cardiac troponin I significantly increased 
in heart injury conditions (p<0.05). Pre-
treatment with three mentioned doses of 
semelil had no significant effect on tro-




CTL group showed a normal electro-
cardiograph pattern. ISO administration 
caused significant changes in ECG versus 
CTL group as shown in Table 2. Different 




Figure 2: Plasma levels of troponin I in different 
animal groups. Values are means ± SEM. All 
groups are significantly different to CTL but 
there is no significant difference among the four 
ISO groups. n = 7-8; * p<0.05. CTL: control, 
ISO: isoproterenol, S1: 1 mg semelil, S5: 5 mg 




In the control group, myocardial cells 
had normal microscopic appearance (Figure 
3). ISO induced mild to moderate heart 
damage as small multifocal degeneration 
with slight degree of inflammatory process 
in 50 % of animals and extensive myofibril-
lar degeneration and/or diffuse inflammato-
ry process in the other 50 % was seen (Fig-
ure 3 and Table 3). Pre-treatment with sem-
elil was somewhat associated with increase 
of the intensity of leukocyte infiltration and 
myocardial necrosis but this reached to sta-
tistically significant difference only in the 
S1+ISO group (p<0.5) (Table 3).  
 
 













- - - - - 6 CTL (n=7) 
1 3 7 1 1 - ISO ( n=8) 
- 3 6 4 1 - S1+ISO (n=7) 
- 3 4 3 1  S5+ISO(n=7) 
1 6 6 4 - - S10+ISO(n=7) 
n: number of animals, ISO: isoproterenol, S1: 1 mg semelil, S5: 5 mg semelil, S10: 10 mg semelil 
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Table 3: Histopathological scores and animals number with different degrees of injury in each group  
Groups Myocardial pathology scores 
0 1 2 3 4 Mean 
CTL (n=7) 7 0 0 0 0 0 
ISO ( n=8) 0 0 4 4 0 2.5● 
S1+ISO (n=7) 0 0 1 2 4 3.43*● 
S5+ISO(n=7) 0 0 2 2 3 3.14● 
S10+ISO(n=7) 0 0 1 4 2 3● 
n: number of animals, CTL: control, ISO: isoproterenol, S1: 1 mg semelil, S5: 5 mg semelil, S10: 10 mg semelil, 
pathology scores: 0: nil, 1: minimum (focal myocytes damage), 2: mild (small multifocal degeneration with slight 
degree of inflammatory process), 3: moderate (extensive myofibrillar degeneration and/or diffuse inflammatory 
process), 4: severe (necrosis with diffuse inflammatory process). The number of animals with severe lesion (score 
of 4) were more in semelil groups but only significant in S1+ISO group when compared with ISO group. * p<0.05 






Figure 3: H & E stained sections of heart tissue in 
different animal groups. A, CTL group heart sections 
showing normal appearance of cardiac myofibers. B, 
ISO group that received only isoproterenol (ISO) 
showing mild to moderate myodegeneration of mus-
cle fibers, interstitial edema and inflammatory cell 
infiltration. C, moderate to severe myodegeneration 
along with severe interstitial edema and inflammato-
ry cell infiltration in S1+ISO group. D, moderate to 
severr myodegeneration, severe edema and leuco-
cytes infiltration in S5+ISO group. E, moderate to 
severe myodegeneration, inflammatory process and 
interstitial edema in S10+ISO group. CTL: control, 
ISO: Isoproterenol, S1: 1 mg semelil, S5: 5 mg sem-
elil, S10: 10 mg semelil. The magnification is 400×. 
(↔): interstitial edema, (→): Inflammatory cells, 
(....›): myonecrosis 
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The present study was conducted to as-
sess the effect of semelil on cardiovascular 
system in stressful conditions. High doses 
of isoproterenol, a non selective beta adren-
ergic agonist, by induction of cardiac stress 
cause myocardial injury and this method 
has been accepted as a standard experi-
mental model to induce cardiac dysfunc-
tions and to evaluate following interven-
tions (Rona et al., 1959; Wexler, 1978; 
Joukar et al., 2010a). In agreement with 
previous investigations, the present study 
showed that injection of isoproterenol 
(50 mg/kg) for two successive days was 
associated with significant reduction in my-
ocardial function observed by increase in 
LVEDP and decrease in LVSP and positive 
and negative dp/dt maxes (see Figure 1 and 
Table 1). Increase in plasma cardiac tro-
ponin I, ECG disturbances and mild to 
moderate leukocyte infiltration and myo-
degeneration of the heart muscle was also 
seen. Blood pressure level was slightly de-
creased in animals with heart damage (ISO 
group), but higher doses of semelil was as-
sociated with less reduction in mean arterial 
pressure which may be due to improvement 
in heart perfusion. Previous studies have 
reported positive effect of semelil on tissue 
blood flow (Bahrami et al., 2008). The pre-
sent study showed that semelil at doses of 5 
and 10 mg/kg improved left ventricular 
function of damaged heart by inducing pos-
itive inotropic effect (+dp/dt max, an im-
portant index of myocardial contractility) 
(Koeppen and Stanton, 2008), and positive 
lusitropic effect (-dp/dt max, indicator of 
myocardial relaxation). It also reduced the 
ISO-induced increase in LVEDP (marker of 
heart failure), in a dose-dependent manner. 
To our best knowledge, no study in the lit-
erature has yet investigated the effects of 
semelil on the heart function. Increased cal-
cium influx to cardiac cells and prevention 
of myocardial stunning during heart injury 
may be two possible reasons for positive 
inotropic effect of semelil in higher doses. 
However, confirmation of these possibili-
ties needs future investigations.  
Despite the positive effect of semelil on 
cardiac function, it was associated with 
more intense myocardial damage based on 
histology data (Figure 3). Although the im-
provement of myocardial contractility leads 
to more stroke volume, more cardiac output 
and consequently better blood pressure sta-
bility (Table 1), this could increase cardiac 
workload and oxygen demand leading to 
heart damage in ischemia conditions. In this 
regard, reduction of myocardial energy de-
mands is one of the several approaches for 
declining infarct size in patients with myo-
cardial injury (Zipes et al., 2005). More ex-
tent and exacerbation of heart lesions in 
semelil experiments may be due to in-
creased cardiac load and myocardial oxy-
gen supply limitation resulted from increase 
in contractility that in turn could justify 
high mortality rate in animals that received 
the drug in dose of 20 mg/kg. Today, the 
role of inflammatory processes in the de-
velopment of cardiovascular disease is well 
known (Little et al., 2011). Exacerbation of 
inflammatory process followed by semelil 
injection may be the negative effect of this 
drug on heart tissue. The anti inflammatory 
effect of chronic semelil use has been 
shown in a previous study (Mousavi-Jazi et 
al., 2010). In the present study we used 
semelil only for two consecutive days in 
each treated groups that can be a reason of 
difference between our results with others. 
In addition the heart tissue inflammatory 
response to semelil may be different from 
other tissues.  
Surprisingly the lower dose of semelil 
exacerbated the effect of ISO on blood 
pressure and heart rate. It seems that seme-
lil in this dose has directly suppressed 
pacemaker activity (S-A node) of the heart 
because despite the lowering effect on 
blood pressure (BP) heart rate (HR) was 
also reduced, while it is anticipated that re-
duction in BP causes an increase in HR 
through baro-receptor reflex (sympathetic 
stimulation). In fact reduction of BP may be 
the consequence of reduction in HR and 
hence cardiac output. However, in larger 
doses, semelil recovered BP through im-
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proving myocardial contractility. The evi-
dence for this statement is increase in LVSP 
and reduction in LVEDP in groups that re-
ceived larger doses of semelil (Table 1). 
Therefore semelil should have two different 
mechanisms of action in low and high doses 
and this hypothesis needs further investiga-
tions to prove. 
From ECG point of view, semelil ad-
ministration had no additional effect on ISO 
effect alone. This finding may mean that 
semelil does not affect current injury and 
conduction properties of the heart. Howev-
er, the influence of semelil on incidence of 
cardiac arrhythmia needs complementary 
studies. 
In conclusion the present study showed 
that semelil administration can help to 
maintain the heart contractility and hence 
blood pressure stability in myocardial inju-
ry conditions. However this beneficial ef-
fect may associate with further cardiac inju-
ry due to increased cardiac workload and 
activation of inflammatory process. In long 
term periods, this could lead to deteriora-
tion of the ischemic heart function. It is 
noteworthy that present study examined the 
acute effects of semelil and future studies 
are needed to elucidate the chronic effects 
of this drug on cardiovascular system. 
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